Insmed | INSM - Cost Of Sales

Stock Price
149.32
Daily Change
-0.68 -0.45%
Monthly
-4.21%
Yearly
83.10%
Q1 Forecast
159.80

Insmed reported $46.16M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Cytokinetics USD 99.23M 13.32M Sep/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Insmed USD 46.16M 15.25M Dec/2025
Novartis USD 3.54B 216M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025